

Investment Review

The Hereford/DSM US Large Cap Growth Sub-Fund depreciated (0.66)% for the month of April compared to a 0.50% return for the Russell 1000 Growth Index and a 0.96% return for the S&P 500 including dividends. At the end of April, the Fund was invested primarily in the technology, health care and consumer discretionary sectors, with smaller weights in the financials, materials, industrials and consumer staples sectors.

For the month, the Fund trailed the benchmark by approximately 120 bps. This was primarily the result of the Manager's selections in technology, as well as the Fund's selections and overweight in health care versus the benchmark. In April, the best performing positions in the portfolio were Perrigo, Tencent Holdings, Priceline Group, Affiliated Managers and Starbucks. The worst performers for the month were Biogen, Celgene, Royal Caribbean Cruises, Cognizant Tech Solutions and Actavis.

Manager's Commentary

DSM's multi-year global economic outlook of stable 3% type growth remains unchanged. In the US, much of the focus is on the Federal Reserve's possible tightening moves, while in China, Europe and Japan each of the central banks are easing monetary supply. Certainly various geopolitical factors, particularly in the Ukraine and the Middle East, as well as slow growth in Europe and potential issues relating to the situation in Greece, provide cause for concern. However these dynamics are well known to investors and we continue to feel comfortable with our long-standing forecast.

Fourth quarter GDP growth in the US was recently reported at 2.2% annualized, driven by consumer spending, especially in healthcare, but offset by weaker inventory growth. Given the price of oil, it is of no surprise that weakness in energy sector investment has also had a negative impact. Despite a number of mixed economic reports, the US looks set to continue on its 2% plus annual growth rate. Reports confirming low inflation and continued slow and steady employment gains have caused many observers to push the Federal Reserve's long expected first rate hike to the autumn of this year from June. However, with unemployment lower, albeit in part driven by workers dropping out of the workforce, and with wage gains beginning to accelerate, we believe a rate hike is approaching. In short, the timing of the rate hike remains "data dependent." In Europe slow economic growth remains the primary issue, with unemployment in the Eurozone in excess of 11%, although there are some signs of improving employment trends. The weaker Euro may well aid economic growth, while the ECB's anti-deflationary quantitative easing policies could prove supportive as well. The discussions over Greek debt continue. Greece remains insistent that it renegotiate its obligations, which implies that a portion of the debt will be written off, and with that exists the threat of Greece leaving the European Union. We are "cautiously optimistic" that economic growth in China will remain in the 6% to 7% range, even as China's government continues its economic reform program which, at its core, emphasizes a significant anti-corruption effort in all areas of the economy. However, the government also remains active with pro-growth initiatives. Japan's economic growth should remain modestly positive, in the 1% to 2% range. Perhaps the most significant news from Japan is the slowly accelerating pace of change in corporate governance. Japanese corporations are famous for their huge piles of dormant cash, which are rarely utilized for any productive economic purpose. However, new board members and governmental pressure, along with pleas from shareholders, may begin to motivate managements to allocate the excess capital to more productive purposes.


The portfolio continues to be focused on unique global businesses that have been identified, and are continuously subject to analysis, by our ten-member investment team. We believe that the valuation of the portfolio, at 20.3x next-four-quarter earnings through March of 2016, and 17.8x 2016 earnings, based on our calculations, continues to be attractive in the current slow growth economic environment and relative to the market. We also continue to project a mid-to-high "teens" earnings growth rate through 2018. Additionally, the portfolio holdings remain characterized by strong balance sheets and significant free cash flow.

Key Information

| | | | |
|-------------------------------------|-------------|------------------|------------------------------|
| NAV A Shares (30/01/15) | US\$ 152.23 | Strategy Assets | US\$ 4,679.1m ^(a) |
| Total Fund Size (all share classes) | US\$ 130.1m | Fund Launch Date | 29-Nov-07 |

| Monthly Performance (%) | | | | | | | | | | | | | |
|------------------------------------|------|-----|------|------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | YTD |
| HF-DSM US LCG | -1.5 | 5.9 | -0.1 | -0.7 | | | | | | | | | 3.6 |
| Russell 1000 Growth ^(c) | -1.5 | 6.7 | -1.1 | 0.5 | | | | | | | | | 4.4 |
| S&P 500 ^(c) | -3.0 | 5.7 | -1.6 | 1.0 | | | | | | | | | 1.9 |

| Period Performance (%) | YTD | 2014 | 2013 | 2012 | 2011 | 2009 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | Cumulative | Annualised |
|--------------------------------------|-----|------|------|------|-------|------|------|--------|------|------|------|------|------|------------|------------|
| HF-DSM US LCG Returns ^(b) | 3.6 | 9.7 | 34.1 | 18.2 | (2.0) | 21.9 | 22.8 | (39.3) | 18.7 | 9.8 | 11.4 | 9.4 | 25.2 | 149.4 | 7.4% |
| Russell 1000 Growth ^(c) | 4.4 | 13.1 | 33.5 | 15.3 | 2.6 | 16.7 | 37.2 | (38.4) | 11.8 | 9.1 | 5.3 | 6.3 | 29.7 | 121.4 | 6.6% |
| S&P 500 ^(c) | 1.9 | 13.7 | 32.4 | 16.0 | 2.1 | 15.1 | 26.5 | (37.0) | 5.5 | 15.8 | 4.9 | 10.9 | 28.7 | 125.8 | 6.7% |



HF Hereford Funds

| Top Ten Holdings | |
|--------------------------------|--------------------|
| Actavis | Dollar Tree |
| Affiliated Managers Group | Google (Cl. A & C) |
| Biogen | Priceline Group |
| Celgene | Starbucks |
| Cognizant Technology Solutions | Visa |

| Sectoral Breakdown | % of Assets |
|------------------------|-------------|
| Information Technology | 29.3% |
| Health Care | 28.1% |
| Consumer Discretionary | 24.6% |
| Financials | 8.6% |
| Materials | 3.5% |
| Industrials | 2.7% |
| Consumer Staples | 1.8% |

Investment Objective

The investment objective of the HF DSM US LCG is to provide capital appreciation principally through investments in US based growing corporations with market capitalizations generally above US\$5 billion. These companies are chosen for their growth prospects, attractive returns, solid business fundamentals and intelligent management. The sub fund may, on an ancillary basis, invest in US-based companies with lower market capitalizations as well as in non-US based companies. The Compartment may invest in American Depository Receipts and American Depository Shares. The reference benchmark for this strategy is the Russell 1000 Growth Index.

| Fund Codes | |
|------------|--------------|
| Bloomberg | DSMUSLA LX |
| ISIN | LU0327604228 |
| Reuters | LP65102015 |
| Sedol | B28TLX2 |
| | 3504726 |
| WKN | A0M58T |

| Since inception | HF-DSM US LCG | HF-DSM US LCG Composite | R1000 Growth |
|-------------------|---------------|-------------------------|--------------|
| Volatility | n/a | 14.7 | 15.0 |
| Sharpe Ratio | n/a | 0.4 | 0.4 |
| Information Ratio | n/a | 0.1 | |
| Tracking Error | n/a | 6.7 | |
| Beta | n/a | 0.9 | |
| Alpha | n/a | 1.5 | |

| Fund Details | |
|--------------------|--|
| Dealing Day | Daily |
| Dividends | None - income accumulated within the fund |
| Investment Manager | DSM Capital Partners LLC 116 Radio Circle Drive, Suite 200, Mount Kisco, NY 10549, USA |
| Management Company | BSI Fund Management S.A. 44F, rue de la Vallée, L-2661 Luxembourg |
| Custodian | BSI Europe S.A. 122, Rue Adolphe Fischer L-1521 Luxembourg |
| Legal Advisers | Elvinger, Hoss & Prussen 2 Place Winston Churchill, L-1340 Luxembourg |
| Auditor | Deloitte Audit S.à.r.l. 560 Rue de Neudorf, L-2220 Luxembourg |

| Annual Management Charge | |
|----------------------------------|-------|
| Share Class A & U ^(e) | 1.25% |
| Share Class D ^(f) | 1.75% |

| Minimum Investment | |
|----------------------------------|---|
| Share Class A & U ^(e) | \$100,000 initial / \$10,000 subsequent |
| Share Class D | \$10,000 initial / \$1,000 subsequent |

Order Transmission Information

Original Applications To:

UBS Fund Services
Attn.: Transfer Agent
33a avenue J.F. Kennedy
L-1855 Luxembourg

Subsequent Applications Only Via Facsimile:

UBS Fund Services
Attn.: Transfer Agent
Tel: (+352) 4410106417
Fax: (+352) 4410106410
Email: sh-ubsfsl-transferagent@ubs.com

- This refers to the total assets invested in the reference strategy managed by the Investment Manager.
- Data and graph depict DSM Composite through November 2007 and Hereford Funds DSM US Large Cap Growth Fund Class A thereafter. Historical gross performance of DSM Large Cap Composite returns (the Reference Strategy) is net of modeled fee and expense typical of Hereford Funds DSM US Large Cap Growth Fund Class A (1.25% fee + 0.25% expense). Fund follows same strategy. Performance presentation incomplete without accompanying footnotes as shown at www.dsmcapital.com.
- Total return including dividends.
- The fund is registered with the BaFin for public distribution in Germany from 17/10/12, registered with the AFM for public distribution in the Netherlands and registered with the AMF for public distribution in France.
- Share Class U has been granted Reporting Status by HMRC as of October 1, 2010.
- Share Class D is German tax registered from October 1, 2010.

France - Centralizing Correspondent as defined by French Regulation:
Société Générale - Order Desk, 32, avenue du Champ de Tir, BP 81236, F-44312 Nantes Cedex 3
Phone: +33/2.51.85.66.40, Fax: +33/2.51.85.58.71

Germany - Paying Agent as defined by German Regulation:
Marcard, Stein & Co - Ballindamm 36, 20095 Hamburg
Phone: +49/40.32.099.556, Fax: +49/40.32.099.206

Switzerland - Representative and Paying Agent as defined by Swiss Regulation:
Société Générale, Zurich Branch, Talacker, 50, P.O. Box 1928, CH-8021 Zurich
Phone: +41/58.272.34.18 Fax: +41/58.272.35.49

This document is for information purposes only. It is neither an advice nor a recommendation to enter into any investment. Investment suitability must be determined for each investor, and this fund may not be suitable for all investors. This information does not provide any accounting, legal, regulatory or tax advice. Investors should consult professional advisers to evaluate this information. An investment should be made only on the basis of the Prospectus, the annual and any subsequent semi-annual reports of HEREFORD FUNDS (the "Fund"), a société d'investissement à capital variable, established in Luxembourg and registered under Part I of Luxembourg law of 20 December, approved by the Commission de Surveillance du Secteur Financier (CSSF). These can be obtained from the Fund, from BSI Fund Management S.A., 44F, rue de la Vallée, L-2661 Luxembourg, and any distributor or intermediary appointed by the Fund. No warranty is given, in whole or in part, regarding performance of the Fund. There is no guarantee that its investment objectives will be achieved. Earnings projections are not guarantees of future results and there is no representation that the securities discussed were or will be profitable. Investors should be aware that the value of investments can fall as well as rise and that they may not recover the full amount invested. Past performance is no guide to future performance. The information provided in this document may be subject to change without any warning or prior notice and should be read in conjunction with the most recent publication of the Prospectus of the Fund. While great care is taken to ensure that this information is accurate, no responsibility can be accepted for any errors, mistakes or omission or for future returns. This document is intended for the use of the addressee only and may not be reproduced, redistributed, passed on or published, in whole or in part, for any purpose, without the prior written consent of HEREFORD FUNDS. Neither the CSSF nor any other regulator has approved this document. Full details of the investment policy and objectives are stated in the Prospectus.